Amineptine (or SURVECTOR®) was mainly prescribed to treat major depressive disorder.
Class: Atypical, Tricyclic (TCA)
FDA Approval: International Only (Europe)
Dosage Forms: N/A
Biological Half-life: 0.8-1 hour
Side Effects: Dizziness, blurred vision, dry mouth, nausea, constipation, appetite changes, hyperhidrosis, sex drive changes
Routes of Administration: Oral
Pregnancy Category: N/A